山(shan)(shan)東(dong)金(jin)(jin)(jin)城(cheng)(cheng)醫(yi)(yi)(yi)藥(yao)集(ji)團(tuan)股(gu)份有(you)限(xian)公(gong)司(簡稱“金(jin)(jin)(jin)城(cheng)(cheng)醫(yi)(yi)(yi)藥(yao)”,股(gu)票(piao)代碼(ma):300233)成(cheng)立(li)于2004年(nian),創業(ye)板上市企(qi)業(ye)。目前,公(gong)司擁(yong)有(you)北京朗(lang)依制(zhi)藥(yao)有(you)限(xian)公(gong)司、上海金(jin)(jin)(jin)城(cheng)(cheng)藥(yao)業(ye)有(you)限(xian)公(gong)司、廣(guang)東(dong)金(jin)(jin)(jin)城(cheng)(cheng)金(jin)(jin)(jin)素制(zhi)藥(yao)有(you)限(xian)公(gong)司、山(shan)(shan)東(dong)金(jin)(jin)(jin)城(cheng)(cheng)生物(wu)藥(yao)業(ye)有(you)限(xian)公(gong)司、山(shan)(shan)東(dong)金(jin)(jin)(jin)城(cheng)(cheng)醫(yi)(yi)(yi)藥(yao)化(hua)工有(you)限(xian)公(gong)司、山(shan)(shan)東(dong)金(jin)(jin)(jin)城(cheng)(cheng)石墨烯科技有(you)限(xian)公(gong)司、意大(da)利(li)海寶露(lu)有(you)限(xian)責任(ren)公(gong)司等18家(jia)參(can)控股(gu)公(gong)司。公(gong)司通過“實(shi)業(ye)+資本”雙(shuang)輪(lun)驅動發展模式,已構(gou)建形成(cheng)獨具金(jin)(jin)(jin)城(cheng)(cheng)特(te)色(se)的(de)醫(yi)(yi)(yi)藥(yao)健(jian)康制(zhi)藥(yao)工業(ye)產(chan)業(ye)鏈,業(ye)務范圍涉及生物(wu)制(zhi)藥(yao)、頭(tou)孢(bao)類醫(yi)(yi)(yi)藥(yao)中間體、特(te)色(se)原料藥(yao)、終端制(zhi)劑、保健(jian)品、新(xin)材(cai)料等產(chan)業(ye)領域(yu),并(bing)現(xian)已形成(cheng)年(nian)營業(ye)收入超(chao)20億(yi)元(yuan)、總資產(chan)近(jin)50億(yi)的(de)產(chan)業(ye)規模。
山東金城醫(yi)藥(yao)(yao)集(ji)團股份(fen)有(you)限公(gong)司是(shi)(shi)以(yi)三、四代頭孢(bao)類醫(yi)藥(yao)(yao)中間(jian)體(ti)(ti)、特色原料藥(yao)(yao)、生物制(zhi)藥(yao)(yao)、終端制(zhi)劑以(yi)及婦兒產(chan)(chan)品(pin)等為主(zhu)業的(de)科研、生產(chan)(chan)企業,其中,頭孢(bao)類醫(yi)藥(yao)(yao)中間(jian)體(ti)(ti)產(chan)(chan)品(pin)銷量、銷售收入(ru)連續多年位居行業前列,是(shi)(shi)重要(yao)的(de)生物制(zhi)藥(yao)(yao)生產(chan)(chan)基地以(yi)及國內醫(yi)藥(yao)(yao)健康產(chan)(chan)業集(ji)團。主(zhu)導產(chan)(chan)品(pin)有(you)谷胱甘肽(花青肽美品(pin)牌(pai)(pai))、硝呋太爾(er)膠(jiao)囊(朗依(yi)品(pin)牌(pai)(pai))、富馬酸比(bi)索洛(luo)爾(er)膠(jiao)囊(洛(luo)雅品(pin)牌(pai)(pai))、牡蠣(li)碳酸鈣咀嚼片(pian)(金娃寧品(pin)牌(pai)(pai))、復方木香鋁鎂(mei)片(pian)(德(de)瑞(rui)夫品(pin)牌(pai)(pai))等近百種(zhong)。
當(dang)前,公司堅(jian)持科學發展(zhan),按(an)照“大健(jian)康(kang)、大醫藥(yao)(yao),打造具有金(jin)城特(te)(te)色(se)制(zhi)(zhi)藥(yao)(yao)產(chan)(chan)(chan)(chan)業(ye)鏈(lian)(lian)”的(de)產(chan)(chan)(chan)(chan)業(ye)定位和(he)(he)“調(diao)整、轉型(xing)、升級、發展(zhan)”的(de)戰(zhan)略思(si)路,專注專注金(jin)城特(te)(te)色(se)制(zhi)(zhi)藥(yao)(yao)產(chan)(chan)(chan)(chan)業(ye)鏈(lian)(lian)三大方向建(jian)(jian)設(she)——“頭孢類(lei)抗生(sheng)素(su)終端制(zhi)(zhi)劑產(chan)(chan)(chan)(chan)業(ye)鏈(lian)(lian),多(duo)肽(tai)類(lei)特(te)(te)色(se)生(sheng)物制(zhi)(zhi)藥(yao)(yao)產(chan)(chan)(chan)(chan)業(ye)鏈(lian)(lian)和(he)(he)婦科、調(diao)節免疫(yi)制(zhi)(zhi)劑特(te)(te)色(se)類(lei)產(chan)(chan)(chan)(chan)業(ye)鏈(lian)(lian) ”。同時,公司加(jia)快“三個(ge)平(ping)臺(tai)”建(jian)(jian)設(she)(技術創(chuang)(chuang)新平(ping)臺(tai)、產(chan)(chan)(chan)(chan)業(ye)運營平(ping)臺(tai)、組織管(guan)控平(ping)臺(tai)),加(jia)快打造“四支(zhi)隊伍(wu)(wu)(wu)”建(jian)(jian)設(she)(企業(ye)家隊伍(wu)(wu)(wu)、中高層管(guan)理隊伍(wu)(wu)(wu)、專業(ye)人才隊伍(wu)(wu)(wu)、熟練工(gong)人隊伍(wu)(wu)(wu)),積極實踐(jian)內涵(han)式發展(zhan)、外延式擴(kuo)張和(he)(he)投資并購三種(zhong)發展(zhan)方式,著(zhu)力將公司打造成“科技化(hua)、生(sheng)態化(hua)、規范化(hua)、品(pin)牌化(hua)、國際化(hua)”的(de)現代化(hua)醫藥(yao)(yao)健(jian)康(kang)產(chan)(chan)(chan)(chan)業(ye)集團,助推醫藥(yao)(yao)進步,創(chuang)(chuang)享健(jian)康(kang)生(sheng)活,志在成為醫藥(yao)(yao)健(jian)康(kang)產(chan)(chan)(chan)(chan)業(ye)創(chuang)(chuang)新型(xing)領(ling)軍企業(ye)。